Clinical trial
A Phase 3, Single-arm Study Evaluating the Safety and Effectiveness of VX-548 for Acute Pain
NCT05661734 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Single-arm Study Evaluating the Safety and Effectiveness of VX-548 for Acute Pain
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 9, 2023
- Completion date
- December 12, 2023
- Enrollment
- 258 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.